Liu HM - Search Results

1

Degraders in epigenetic therapy: PROTACs and beyond.

Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang SP, Shen L, Wang N, Herdewijn P, Zheng YC, Wang SQ, Chen XB. Dai XJ, et al. Among authors: liu gz, liu hm. Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024. Theranostics. 2024. PMID: 38389844 Free PMC article. Review.

2

Triazole-fused pyrimidines in target-based anticancer drug discovery.

Dai XJ, Xue LP, Ji SK, Zhou Y, Gao Y, Zheng YC, Liu HM, Liu HM. Dai XJ, et al. Among authors: liu hm. Eur J Med Chem. 2023 Mar 5;249:115101. doi: 10.1016/j.ejmech.2023.115101. Epub 2023 Jan 11. Eur J Med Chem. 2023. PMID: 36724635 Review.

3

Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells.

Dai XJ, Zhao LJ, Yang LH, Guo T, Xue LP, Ren HM, Yin ZL, Xiong XP, Zhou Y, Ji SK, Liu HM, Liu HM, Liu Y, Zheng YC. Dai XJ, et al. Among authors: liu y, liu hm. J Med Chem. 2023 Mar 23;66(6):3896-3916. doi: 10.1021/acs.jmedchem.2c01593. Epub 2023 Mar 1. J Med Chem. 2023. PMID: 36856685

4

Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer.

Liu HM, Xiong XP, Wu JW, Chen HX, Zhou Y, Ji SK, Dai XJ, Zheng YC, Liu HM. Liu HM, et al. Eur J Med Chem. 2023 May 5;251:115255. doi: 10.1016/j.ejmech.2023.115255. Epub 2023 Mar 9. Eur J Med Chem. 2023. PMID: 36913900

5

Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer.

Dai XJ, Liu Y, Wang N, Chen HX, Wu JW, Xiong XP, Ji SK, Zhou Y, Shen L, Wang SP, Liu HM, Liu HM, Zheng YC. Dai XJ, et al. Among authors: liu y, liu hm. Eur J Med Chem. 2023 Nov 5;259:115684. doi: 10.1016/j.ejmech.2023.115684. Epub 2023 Jul 29. Eur J Med Chem. 2023. PMID: 37542989

6

LSD1 in drug discovery: From biological function to clinical application.

Liu HM, Zhou Y, Chen HX, Wu JW, Ji SK, Shen L, Wang SP, Liu HM, Liu Y, Dai XJ, Zheng YC. Liu HM, et al. Among authors: liu y. Med Res Rev. 2024 Mar;44(2):833-866. doi: 10.1002/med.22000. Epub 2023 Nov 28. Med Res Rev. 2024. PMID: 38014919 Review.

7

CD155 as an emerging target in tumor immunotherapy.

Wu JW, Liu Y, Dai XJ, Liu HM, Zheng YC, Liu HM. Wu JW, et al. Among authors: liu y, liu hm. Int Immunopharmacol. 2024 Apr 20;131:111896. doi: 10.1016/j.intimp.2024.111896. Epub 2024 Mar 22. Int Immunopharmacol. 2024. PMID: 38518596 Review.

8

SMARCA4 (BRG1) activates ABCC3 transcription to promote hepatocellular carcinogenesis.

Liu H, Yue L, Hong W, Zhou J. Liu H, et al. Life Sci. 2024 Jun 15;347:122605. doi: 10.1016/j.lfs.2024.122605. Epub 2024 Apr 18. Life Sci. 2024. PMID: 38642845

9

Temporal regulation of MDA5 inactivation by Caspase-3 dependent cleavage of 14-3-3η.

Chan YJ, Liu NT, Hsin F, Lu JY, Lin JY, Liu HM. Chan YJ, et al. Among authors: liu hm. PLoS Pathog. 2024 Jun 6;20(6):e1012287. doi: 10.1371/journal.ppat.1012287. Online ahead of print. PLoS Pathog. 2024. PMID: 38843304 Free article.

10

Associations of diabetes status and glucose measures with outcomes after endovascular therapy in patients with acute ischemic stroke: an analysis of the nationwide TREAT-AIS registry.

Hsieh MT, Hsieh CY, Yang TH, Sung SF, Hsieh YC, Lee CW, Lin CJ, Chen YW, Lin KH, Sung PS, Tang CW, Chu HJ, Tsai KC, Chou CL, Lin CH, Wei CY, Chen TY, Yan SY, Chen PL, Hsiao CY, Chan L, Huang YC, Liu HM, Tang SC, Lee IH, Lien LM, Chiou HY, Lee JT, Jeng JS. Hsieh MT, et al. Among authors: liu hm. Front Neurol. 2024 May 15;15:1351150. doi: 10.3389/fneur.2024.1351150. eCollection 2024. Front Neurol. 2024. PMID: 38813247 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,614 results

Search Page